Apr. 23, 2021
By: Jonathan M Block, SA News Editor
Shares of Brooklyn ImmunoTherapeutics (NYSEMKT:BTX) hit a new 52-week high this morning and are currently up 37%.
Shares are up nearly 97% in the last five days alone.
Earlier this month, the company acquired a license for a mRNA technology platform and brought in a new CEO.
The company's sole asset, IRX-2, is in phase 2b for squamous cell cancer of the head and neck and results are expected by the end of 1H 2021.
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM